US regulators approve new non-opioid drug to treat acute pain | US news

The health organizer said on Thursday, when the US Food and Drug Administration agreed to a new drug to treat acute pain.

Vertex Pharmaceuticals, Journavx brand, works by preventing pain signals in their source, unlike the opioid substances, which lead to brain reward centers while traveling through the blood and then attached to nerve receptors, which leads to addiction and ill -treatment.

The Food and Drug Administration (FDA) said in a statement on Thursday that Journavx is the first approved drug in a new class of pain management.

At a cost of $ 15.50 per 50 mg of birth control pills, the drug is expensive, but people can save addiction.

“We had no really new tools that have come for a long time,” said Richard Rosenkit, head of the Pain Management Department at Cleveland Clinic.

“If this medicine comes, and he has a drug profile that contains it and is in a competitive price segment, then he will see quickly absorbing.”

However, questions have been raised about the commercial capabilities of the drug, as insurance companies and health hospitals may still prefer to prescribe opiates.

Stewart Arbuck, chief operational in the company, said before the decision, Vertex focuses on overcoming and reaching insurance coverage obstacles.

In its report, the Institute of Clinical and Economic Review (ICER), an effective monitoring monitoring, said in its report that the VERTEX pain analgesics are effective by cost only at a low price, as cost savings will be primarily due to avoiding cases of disturbance of the use of opioid materials.

The approval of the FDA (FDA) was based on data from two experiments in the late stage, showing that the drug was greatly reduced from surgical pain compared to imaginary therapy.

Acute pain is a specific disruption as a pain that lasts less than three months. More than 80 million people are prescribed for acute pain every year in the United States, according to Vertex estimates.